

Brain-Derived Neurotrophic Factor val66met genotype interacts with young-adult stress in neurotransmitter regulation of prepulse inhibition in mice

Maarten van den Buuse, John Juan Wen Lee, Emily Jaehne


School of Psychology and Public Health, La Trobe University, Melbourne, Australia

P.1.h.005





BACKGROUND: Brain-derived neurotrophic factor (BDNF) plays an important role in brain development and neuroplasticity and cognition in adulthood. The common BDNF val66met polymorphism results in reduced activity-dependent BDNF release in the brain and has been implicated in aspects of schizophrenia. BDNF levels in the brain and plasma are altered by developmental stress, which is a well-recognized risk factor in schizophrenia development. However it remains unclear by which neurotransmitter mechanisms the BDNF val66met polymorphism may be involved in schizophrenia.

AIM: to investigate the role of the BDNF val66met polymorphism and its interaction with developmental stress in neurotransmitter regulation of prepulse inhibition (PPI), a measure of sensorimotor gating which is disrupted in schizophrenia.



METHODS: We used BDNF^{Val66Met} mice genetically modified to carry a humanized BDNF transcript with the Val66Met polymorphism (hBDNF^{Val66Met}). We studied long-term effect of chronic corticosterone (CORT) exposure (25mg/L drinking water from 6-9 weeks of age) in these animals as a model of history of stress. PPI was assessed in adulthood using standard methodology. We assessed the effects of pseudo-randomized acute treatment with the dopamine receptor agonist, apomorphine (APO), and the NMDA receptor antagonist, MK-801. There were n=18-24 per group with males and females combined; no sex differences were observed in the present study.



RESULTS: Apomorphine (APO): Analysis of the effect of 1mg/kg and 3mg/kg of APO on PPI revealed an APO x CORT interaction and an APO x PP x CORT x genotype interaction, suggesting differential drug effects depending on CORT treatment or genotype. In control Val/Val mice these doses of APO did not affect PPI (A). In contrast, in CORT-pretreated Val/Val mice APO significantly disrupted PPI (A). In Val/Met and Met/Met mice, APO dose-dependently disrupted PPI irrespective of CORT pretreatment (B, C). The effect of APO on startle was greater in Val/Met and Met/Met mice than Val/Val mice independent of prior CORT (D).

MK-801: Acute treatment with MK-801 disrupted PPI (E) and reduced startle (F) independent of genotype or CORT pretreatment.

CONCLUSION: BDNF Val/Met and Met/Met genotypes display greater sensitivity than the Val/Val genotype to disruption of PPI by dopamine receptor stimulation, but not NMDA receptor antagonism. A prior history of stress, here modelled by chronic CORT administration, enhanced the effects of APO in Val/Val mice but had no further effect in the other genotypes which were already responsive to dopamine receptor stimulation-induced PPI disruption. Thus, the BDNF val66met genotype determines sensitivity to dopaminergic disruption of PPI, a model of sensorimotor gating which is an endophenotype of schizophrenia. The BDNF Val66Met genotype also determines differential sensitivity to developmental stress.